rupiya.io
⠋Loading...
0%
❯ Processing cash flow data...
Gland Pharma Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Gland Pharma Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | ₹2,633 Cr | ₹3,463 Cr | ₹4,401 Cr | |||
| Expenses | ₹1,678 Cr | ₹2,161 Cr | ₹2,890 Cr | |||
| Operating Profit | ₹955 Cr | ₹1,302 Cr | ₹1,510 Cr | |||
| OPM % | 36.0% | 38.0% | 34.0% | |||
| Other Income | ₹139 Cr | ₹135 Cr | ₹224 Cr | |||
| Depreciation | ₹95 Cr | ₹99 Cr | ₹110 Cr | |||
| Interest | ₹7 Cr | ₹3 Cr | ₹5 Cr | |||
| Profit Before Tax | ₹993 Cr | ₹1,335 Cr | ₹1,619 Cr | |||
| Tax | ₹993 Cr | ₹1,335 Cr | ₹1,619 Cr | |||
| Net Profit | ₹773 Cr | ₹997 Cr | ₹1,212 Cr | |||
| EPS (₹) | 49.9 | 60.9 | 73.8 | |||
| Dividend Payout % | 0% | 0% | 0% |
Register free to see 3 more years.
| Quarter | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹785 Cr | ₹1,209 Cr | ₹1,373 Cr | ₹1,545 Cr | ||||||||
| Expenses | ₹617 Cr | ₹915 Cr | ₹1,049 Cr | ₹1,189 Cr | ||||||||
| Operating Profit | ₹168 Cr | ₹294 Cr | ₹324 Cr | ₹356 Cr | ||||||||
| OPM % | 21.0% | 24.0% | 24.0% | 23.0% | ||||||||
| Depreciation | ₹38 Cr | ₹65 Cr | ₹81 Cr | ₹105 Cr | ||||||||
| Interest | ₹2 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ||||||||
| Net Profit | ₹79 Cr | ₹194 Cr | ₹194 Cr | ₹192 Cr | ||||||||
| EPS (₹) | 4.8 | 11.8 | 11.8 | 11.7 |
Register free to see 8 more quarters.
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹16 Cr | ₹16 Cr | ₹16 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹3,631 Cr | ₹5,887 Cr | ₹7,141 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹5 Cr | ₹4 Cr | ₹5 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹435 Cr | ₹589 Cr | ₹671 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹4,086 Cr | ₹6,496 Cr | ₹7,834 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹968 Cr | ₹954 Cr | ₹1,502 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹0 Cr | ₹155 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹2,929 Cr | ₹5,204 Cr | ₹5,986 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹4,086 Cr | ₹6,496 Cr | ₹7,834 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 3 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2021 | ₹701 Cr | ₹-761 Cr | ₹-7 Cr | — |
| Mar 2022 | ₹605 Cr | ₹-1,520 Cr | ₹1,238 Cr | — |
| Mar 2023 | ₹791 Cr | ₹-999 Cr | ₹35 Cr | — |
| Mar 2024 | ||||
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 3 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.